STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

ARWR ARROWHEAD PHARMACEUTICALS INCORPORATED StockScouter® Report

2

StockScouter® Score

ARROWHEAD PHARMACEUTICALS INCORPORATED, a mid cap growth company in the healthcare sector, is expected to slightly underperform the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Moving average analysis for ARWR suggests strong price movement over the medium term. Positive

 

Concerns

  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • Earnings growth in the past year has decelerated rapidly compared to earnings growth in the past three years. Negative
  • The most recent quarterly earnings report was slightly lower than analysts’ consensus forecast. Neutral/Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be out of favor, growth stocks will be out of favor, and healthcare stocks will be out of favor.

Expected Risk/Return

Progress: 60% done.
Progress: 40% done.
Low
High

Core Model Grades

F
D
F
B

Previous Ratings

3
4
4